Test-firing ammunition for spliceosome inhibition in cancer

摘要

E7107 is a derivative of the pladienolide family of natural product spliceosome inhibitors, which targets the U2 small nuclear ribonucleoprotein (snRNP) subunit SF3b. The results of a first-in-man trial with E7107 have been reported, representing an important translational step towards the goal of modulating RNA splicing for cancer therapy.